Supriya Lifescience Limited — PPTs, 27-05-2026: Investor Presentation

**Business Performance:** Supriya Lifescience saw robust Q4 FY26 with Revenue up 50% YoY to Rs 276.53 Cr and PAT rising 47% YoY to Rs 74.23 Cr. For FY26, Revenue grew 19% to Rs 827.87 Cr and PAT was up 11% to Rs 209.12 Cr. Europe contributed significantly.

**Growth Drivers or Strategy:** The company's backward-integrated model, accounting for 76% of FY26 revenue, underpins cost efficiency. Focus on aggressive R&D for 3-4 new products annually and major capacity expansion, including new blocks and debottlenecking.

**Recent Developments:** Successfully launched Cardio Vascular, ADHD, and Liquid Anesthetic products. New vitamin block operational. Further capacity expansion via an 'F' block and nasal line is in progress.

**Key Financial Metrics:** FY26 EPS at INR 25.98. Healthy EBITDA and PAT margins show efficient operations.

**Management Outlook:** Developing 30 finished dosage products. Exploring CMO/CDMO in specialized areas. Expanding API customer base in Japan, EU, US, with 6 EU dossier filings planned, indicating robust future growth.